尿液纤维化标志物与肾移植受者移植物衰竭风险:FAVORIT试验的病例-队列辅助研究
该病例-队列研究基于FAVORIT试验,随机选取491名受者并纳入257例移植物衰竭者,检测基线尿α1-微球蛋白(A1M)、单核细胞趋化蛋白1(MCP-1)及Ⅲ型和Ⅰ型前胶原氨基端前肽。校正人口学、CKD危险因素、eGFR和ACR后,尿A1M每倍增HR 1.73(95%CI 1.43-2.08)、MCP-1每倍增HR 1.60(95%CI 1.32-1.93)与移植物衰竭强烈相关;进一步校正其他尿液标志物后仍相关。
要点
- 尿A1M每倍增与移植物衰竭相关,校正eGFR和ACR后HR 1.73(95%CI 1.43-2.08)。
- 尿MCP-1每倍增与移植物衰竭相关,校正eGFR和ACR后HR 1.60(95%CI 1.32-1.93)。
- 尿Ⅲ型和Ⅰ型前胶原水平与移植物衰竭无关联。
核心结论
- 尿小管间质纤维化标志物检测可能提供一种无创方法,识别未来移植物衰竭风险较高的肾移植受者,其价值超越eGFR和尿ACR。
研究设计与样本
- FAVORIT试验为随机双盲试验,测试维生素治疗降低同型半胱氨酸水平对稳定肾移植受者的影响。
- 本研究为病例-队列研究,随机选取491名参与者,并纳入随访期间全部移植物衰竭者257例。
- 预测因素为基线点尿标本中4种与活检小管间质纤维化相关的尿液蛋白:α1-微球蛋白(A1M)、单核细胞趋化蛋白1(MCP-1)、Ⅲ型和Ⅰ型前胶原氨基端前肽。
- 结局为死亡删失的移植物衰竭。
主要发现
- 校正人口学、慢性肾脏病危险因素、eGFR和ACR后,尿A1M每倍增HR 1.73(95%CI 1.43-2.08),尿MCP-1每倍增HR 1.60(95%CI 1.32-1.93),与移植物衰竭强烈相关。
- 进一步校正其他尿液纤维化标志物及多种尿液损伤标志物浓度后,尿A1M每倍增HR 1.76(95%CI 1.27-2.44),尿MCP-1每倍增HR 1.49(95%CI 1.17-1.89),仍与移植物衰竭相关。
- 尿Ⅲ型和Ⅰ型前胶原水平与移植物衰竭无关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 缺乏肾脏活检数据、BK滴度和HLA抗体状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Kidney tubulointerstitial fibrosis marks risk for allograft failure in kidney transplant recipients, but is poorly captured by estimated glomerular filtration rate (eGFR) or urine albumin-creatinine ratio (ACR). Whether urinary markers of tubulointerstitial fibrosis can noninvasively identify risk for allograft failure above and beyond eGFR and ACR is unknown. STUDY DESIGN: Case-cohort study. SETTING & PARTICIPANTS: The FAVORIT (Folic Acid for Vascular Outcome Reduction in Transplantation) Trial was a randomized double-blind trial testing vitamin therapy to lower homocysteine levels in stable kidney transplant recipients. We selected a subset of participants at random (n=491) and all individuals with allograft failure during follow-up (cases; n=257). PREDICTOR: Using spot urine specimens from the baseline visit, we measured 4 urinary proteins known to correlate with tubulointerstitial fibrosis on biopsy (urine α1-microglobulin [A1M], monocyte chemoattractant protein 1 [MCP-1], and procollagen type III and type I amino-terminal amino pro-peptide). OUTCOME: Death-censored allograft failure. RESULTS: In models adjusted for demographics, chronic kidney disease risk factors, eGFR, and ACR, higher concentrations of urine A1M (HR per doubling, 1.73; 95% CI, 1.43-2.08) and MCP-1 (HR per doubling, 1.60; 95% CI, 1.32-1.93) were strongly associated with allograft failure. When additionally adjusted for concentrations of other urine fibrosis and several urine injury markers, urine A1M (HR per doubling, 1.76; 95% CI, 1.27-2.44]) and MCP-1 levels (HR per doubling, 1.49; 95% CI, 1.17-1.89) remained associated with allograft failure. Urine procollagen type III and type I levels were not associated with allograft failure. LIMITATIONS: We lack kidney biopsy data, BK titers, and HLA antibody status. CONCLUSIONS: Urine measurement of tubulointerstitial fibrosis may provide a noninvasive method to identify kidney transplant recipients at higher risk for future allograft failure, above and beyond eGFR and urine ACR.
引用
- Ix JH, Katz R, Bansal N, et al. Urine Fibrosis Markers and Risk of Allograft Failure in Kidney Transplant Recipients: A Case-Cohort Ancillary Study of the FAVORIT Trial. Am J Kidney Dis. 2016. PMID: 28024930. doi:10.1053/j.ajkd.2016.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。